We are live on ! Find out more
VEA

Virtus ETF Advisers Portfolio holdings

AUM $215M
1-Year Est. Return 53.68%
This Fund
S&P 500
This Quarter Est. Return
+25.81%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$241M
AUM Growth
+$50.3M
Cap. Flow
+$11.8M
Cap. Flow %
4.88%
Top 10 Hldgs %
9.37%
Holding
372
New
47
Increased
146
Reduced
160
Closed
17

Top Buys

Rank Stock Value
1
BEPC icon
Brookfield Renewable
BEPC
+$1.51M
2
WES icon
Western Midstream Partners
WES
+$926K
3
PSXP
PHILLIPS 66 PARTNERS LP
PSXP
+$707K
4
DK icon
Delek US
DK
+$681K
5
CVI icon
CVR Energy
CVI
+$669K

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$1.61M
2
AIMT
Aimmune Therapeutics
AIMT
+$1.13M
3
AIV
Aimco
AIV
+$1.1M
4
VIV icon
Telefônica Brasil
VIV
+$1.01M
5
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
+$988K

Sector Composition

Rank Sector Weight
1 Healthcare 29.53%
2 Real Estate 18.96%
3 Energy 16.61%
4 Materials 11.31%
5 Utilities 7.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KIO
151
KKR Income Opportunities Fund
KIO
$452M
$411K 0.17%
28,471
-3,308
-10% -$46.1K
MRNA icon
152
Moderna
MRNA
$22.1B
$410K 0.17%
3,925
-1,049
-21% -$106K
BGB
153
Blackstone Strategic Credit 2027 Term Fund
BGB
$500M
$409K 0.17%
32,737
-3,591
-10% -$44.1K
HTGC icon
154
Hercules Capital
HTGC
$3.04B
$407K 0.17%
28,203
-12,839
-31% -$163K
GSBD icon
155
Goldman Sachs BDC
GSBD
$1,000M
$402K 0.17%
21,032
-7,205
-26% -$124K
WHF icon
156
WhiteHorse Finance
WHF
$139M
$389K 0.16%
28,577
+8,408
+42% +$102K
ADAP
157
DELISTED
Adaptimmune Therapeutics
ADAP
$388K 0.16%
71,954
+40,945
+132% +$222K
HYG icon
158
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
$15.9B
$388K 0.16%
+4,442
New +$380K
GAIN icon
159
Gladstone Investment Corp
GAIN
$655M
$382K 0.16%
37,841
-2,943
-7% -$28K
GLAD icon
160
Gladstone Capital
GLAD
$436M
$377K 0.16%
21,287
+6,898
+48% +$112K
TPVG icon
161
TriplePoint Venture Growth BDC
TPVG
$185M
$377K 0.16%
28,932
-7,396
-20% -$89.7K
XENE icon
162
Xenon Pharmaceuticals
XENE
$6.28B
$375K 0.16%
24,381
-1,292
-5% -$15.1K
ARCC icon
163
Ares Capital
ARCC
$13.7B
$368K 0.15%
21,783
-7,861
-27% -$122K
ODT
164
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$366K 0.15%
19,076
+10,941
+134% +$169K
NBP
165
NovaBridge Biosciences American Depositary Shares
NBP
$202M
$364K 0.15%
+7,725
New +$304K
TSLX icon
166
Sixth Street Specialty
TSLX
$1.68B
$364K 0.15%
17,532
-5,874
-25% -$112K
GBDC icon
167
Golub Capital BDC
GBDC
$3.38B
$362K 0.15%
25,618
-6,114
-19% -$83.5K
SGMO
168
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$352K 0.15%
22,554
-5,495
-20% -$64.4K
TGTX icon
169
TG Therapeutics
TGTX
$8.4B
$351K 0.15%
6,743
-11,178
-62% -$378K
HARP
170
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$347K 0.14%
2,088
+340
+19% +$52.5K
BSL
171
Blackstone Senior Floating Rate 2027 Term Fund
BSL
$168M
$346K 0.14%
24,352
-2,478
-9% -$34.4K
SLRC icon
172
SLR Investment Corp
SLRC
$708M
$346K 0.14%
19,773
-2,601
-12% -$44.1K
MGTX icon
173
MeiraGTx Holdings
MGTX
$1.09B
$345K 0.14%
22,763
-594
-3% -$8.39K
BBIO icon
174
BridgeBio Pharma
BBIO
$16.8B
$343K 0.14%
4,820
-5,933
-55% -$286K
ALLK
175
DELISTED
Allakos
ALLK
$342K 0.14%
2,442
-2,109
-46% -$219K
5 6
7
8 9

Similar funds

NCM
NEXTBio Capital Management Menlo Park, California $215M AUM
SSA
SSA Swiss Advisors Zurich $216M AUM 17.86% 1-Year Est. Return
LIWM
Long Island Wealth Management Melville, New York $216M AUM 14.59% 1-Year Est. Return
VFG
V2 Financial group Naperville, Illinois $215M AUM 15.18% 1-Year Est. Return
IAM
Impala Asset Management Palm Beach, Florida $215M AUM 86.77% 1-Year Est. Return
1M
1248 Management Kansas City, Missouri $216M AUM 12.29% 1-Year Est. Return
GC
GatePass Capital Independence, Ohio $214M AUM 29.83% 1-Year Est. Return
RC
Roubaix Capital Denver, Colorado $214M AUM 32.43% 1-Year Est. Return

Virtus ETF Advisers's Q4 2020 Portfolio in Review

As of Q4 2020, Virtus ETF Advisers held 372 positions worth $241M, up 26% from $191M the previous quarter. Its ten largest holdings account for 9.4% of the portfolio.

Virtus ETF Advisers deployed $11.8M of net new capital in Q4 2020, opening 47 new positions and adding to 146 existing holdings. Its largest new stake was Harmony Biosciences: 14,899 shares worth $539K.

By sector, the portfolio is most concentrated in Healthcare at 30% of assets, down from 32% a quarter earlier, followed by Real Estate and Energy.

On the sell side, the largest reduction was Amicus Therapeutics, an estimated $572K trimmed.

  • Virtus ETF Advisers's largest Q4 2020 buy was Harmony Biosciences: 14,899 shares worth $539K.
  • Virtus ETF Advisers added most to Brookfield Renewable in Q4 2020, an estimated $1.51M increase.
  • Virtus ETF Advisers's biggest Q4 2020 reduction was Amicus Therapeutics, cutting an estimated $572K.
  • Virtus ETF Advisers fully exited Immunomedics Inc in Q4 2020, selling an estimated $1.61M.
  • Virtus ETF Advisers's ten largest holdings make up 9.4% of its $241M portfolio in Q4 2020.
  • Virtus ETF Advisers opened 47 new positions and closed 17 in Q4 2020.
  • Virtus ETF Advisers's portfolio value rose 26% quarter-over-quarter to $241M.

Based on Virtus ETF Advisers's 13F filing for Q4 2020, filed 12 Feb 2021.